World Hepatitis Day 2023: Are we close to the target?
作者信息
Hui Rex Wan-Hin, Fung James
机构信息
Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong.
Department of Medicine, School of Clinical Medicine; State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong.
出版信息
Indian J Med Res. 2023 Jan;158(1):1-4. doi: 10.4103/ijmr.ijmr_1250_23.
Abstract
摘要
相似文献
1
World Hepatitis Day 2023: Are we close to the target?2023年世界肝炎日：我们离目标还有多远？
Indian J Med Res. 2023 Jan;158(1):1-4. doi: 10.4103/ijmr.ijmr_1250_23.
2
Infective hepatitis: a problem of world health.传染性肝炎：一个全球健康问题。
Br Med J. 1952 Jun 28;1(4773):1367-71. doi: 10.1136/bmj.1.4773.1367.
3
[World distribution of epidemic hepatitis (Botkin's disease)].[流行性肝炎（博特金氏病）的全球分布]
Vopr Virusol. 1956 May-Jun;1(3):3-11.
4
Viral hepatitis elimination: Towards a hepatitis-free world.消除病毒性肝炎：迈向无肝炎世界。
J Hepatol. 2022 Nov;77(5):1444-1447. doi: 10.1016/j.jhep.2022.06.034. Epub 2022 Jul 27.
5
[Prevention of virus hepatitis from the standpoint of present day research].
Offentl Gesundheitsdienst. 1955 Dec;17(9):331-8.
6
Post hoc, ergo propter hoc? Evaluating a Potential Increase in Childhood Severe Hepatitis in a Post-COVID World.后此故因此？评估新冠疫情后世界儿童严重肝炎潜在增加的情况。
J Pediatric Infect Dis Soc. 2022 Aug 30;11(8):354-356. doi: 10.1093/jpids/piac054.
7
Hepatitis A in day-care centers. A community-wide assessment.日托中心的甲型肝炎。一项全社区范围的评估。
N Engl J Med. 1980 May 29;302(22):1222-7. doi: 10.1056/NEJM198005293022203.
8
The Role of Nonprofit and Nongovernmental Organizations and People With Viral Hepatitis on the Path Toward Hepatitis C Virus Elimination.非营利组织和非政府组织以及病毒性肝炎患者在实现丙型肝炎病毒消除道路上的作用。
J Infect Dis. 2023 Sep 13;228(Suppl 3):S154-S159. doi: 10.1093/infdis/jiad104.
9
Hepatitis A infection in recent international adoptees and their contacts in Minnesota, 2007-2009.2007-2009 年明尼苏达州近期国际收养儿童及其接触者中的甲型肝炎感染。
Pediatrics. 2011 Aug;128(2):e333-8. doi: 10.1542/peds.2010-1840. Epub 2011 Jul 4.
10
Hepatitis A vaccines.甲型肝炎疫苗
Wkly Epidemiol Rec. 2000 Feb 4;75(5):38-44.
引用本文的文献
1
Stakeholder perspectives and the challenges in implementing hepatitis C elimination policy in Pakistan.利益相关者的观点以及巴基斯坦实施丙型肝炎消除政策面临的挑战。
Front Public Health. 2025 Jul 16;13:1540689. doi: 10.3389/fpubh.2025.1540689. eCollection 2025.
2
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?扩大慢性乙型肝炎的治疗指征：我们应该治疗所有患者吗？
Hepatol Int. 2025 Apr;19(2):304-314. doi: 10.1007/s12072-025-10785-8. Epub 2025 Feb 17.
3
MASLD after hepatitis C virus eradication: Do not overlook the cardiometabolic risk factors: Editorial on "Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan".丙型肝炎病毒根除后的代谢相关脂肪性肝病：勿忽视心脏代谢危险因素：关于“台湾一项全国性登记研究：慢性丙型肝炎患者病毒根除后代谢功能障碍相关脂肪性肝病的动态变化”的社论
Clin Mol Hepatol. 2025 Jan;31(1):290-292. doi: 10.3350/cmh.2024.0630. Epub 2024 Aug 7.
本文引用的文献
1
Chronic hepatitis B: a scoping review on the guidelines for stopping nucleos(t)ide analogue therapy.慢性乙型肝炎：关于停止核苷（酸）类似物治疗指南的范围综述
Expert Rev Gastroenterol Hepatol. 2023 May;17(5):443-450. doi: 10.1080/17474124.2023.2196405. Epub 2023 Apr 3.
2
Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023.乙型肝炎病毒感染的筛查和检测：美国疾病预防控制中心推荐 - 2023 年。
MMWR Recomm Rep. 2023 Mar 10;72(1):1-25. doi: 10.15585/mmwr.rr7201a1.
3
Global treatment rate and barriers to direct-acting antiviral therapy: A systematic review and meta-analysis of 146 studies and 1 760 352 hepatitis C virus patients.全球直接抗病毒治疗的治疗率和障碍：对 146 项研究和 1760352 例丙型肝炎病毒患者的系统评价和荟萃分析。
Liver Int. 2023 Jun;43(6):1195-1203. doi: 10.1111/liv.15550. Epub 2023 Mar 8.
4
Global reporting of progress towards elimination of hepatitis B and hepatitis C.全球消除乙型肝炎和丙型肝炎进展报告。
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):332-342. doi: 10.1016/S2468-1253(22)00386-7. Epub 2023 Feb 8.
5
Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective.肝细胞癌的临床实践指南和实际实践：香港的观点。
Clin Mol Hepatol. 2023 Apr;29(2):217-229. doi: 10.3350/cmh.2022.0399. Epub 2022 Dec 28.
6
Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey.新型冠状病毒肺炎大流行对消除乙型和丙型肝炎的影响：欧洲肝脏研究学会调查
JHEP Rep. 2022 Sep;4(9):100531. doi: 10.1016/j.jhepr.2022.100531. Epub 2022 Jul 27.
7
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials.评估乙型肝炎治疗中不断发展的药物治疗领域：关注处于 II 期临床试验阶段的药物。
Expert Opin Emerg Drugs. 2022 Jun;27(2):127-140. doi: 10.1080/14728214.2022.2074977. Epub 2022 May 15.
8
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study.全球丙型肝炎病毒流行率的变化和 2015 年至 2020 年期间的治疗流程：建模研究。
Lancet Gastroenterol Hepatol. 2022 May;7(5):396-415. doi: 10.1016/S2468-1253(21)00472-6. Epub 2022 Feb 16.
9
Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.中国慢性乙型肝炎病毒感染的普遍筛查的成本效益：经济评估。
Lancet Glob Health. 2022 Feb;10(2):e278-e287. doi: 10.1016/S2214-109X(21)00517-9.
10
Hepatitis C virus micro-elimination: Where do we stand?丙型肝炎病毒的微消除：我们处于什么位置？
World J Gastroenterol. 2021 Apr 28;27(16):1728-1737. doi: 10.3748/wjg.v27.i16.1728.
Zotero 插件